Shares of Galena Biopharma Inc. (NASDAQ: GALE), a biotechnology company engaged in the discovery, development and commercialization of therapies addressing unmet medical needs using targeted biotherapeutics, are soaring in trading today.
At last check, GALE shares were trading 15.32% higher at $1.97 on above average volume of 20.70 million. The stock touched an intra-day high of $2.30. It has now gained more than 20% in the last three trading sessions.
GALE shares are soaring today after the company announced the issuance of a key patent from the U.S. Patent and Trademark Office (USPTO). The patent, originally allowed in March 2012, covers the use of GALE’s product candidate, NeuVax™.
Mark J. Ann, Ph. D., President and CEO of Galena Biopharma, said that as GALE continues to make progress with the clinical development of NeuVax, issuance of the patent from the USPTO underscores the company’s commitment to support and advance its proprietary oncology pipeline.
Recent Comments